Introduction:
Financially strong pharma stocks stand out with consistent revenue growth, healthy profits, and robust ROE and ROCE, indicating efficient capital utilisation and operational success. A low debt-to-equity ratio further highlights their financial discipline and stability.
These metrics provide a comprehensive view of companies with sound financial health and operational excellence. Monitoring these indicators can help investors uncover opportunities in the ever-growing pharmaceutical sector.
Sigachi Industries Ltd:
On December 13, 2024, Sigachi Industries Ltd (BSE: SIGACHI) opened at ₹52.77, recorded a high of ₹53.35 and a low of ₹51.50, closing at ₹52.88, up by 0.02%. The company’s market capitalisation stands at ₹1,735.50 crore.
Sigachi Industries Ltd reported a revenue growth from ₹302 crore in FY23 to ₹404 crore in FY24, reflecting robust financial performance. The company achieved an ROE of 16.69% and an ROCE of 16.38%, with a healthy debt-to-equity ratio of 0.29, showcasing efficient operations and financial stability.
Sigachi Industries Ltd produces microcrystalline cellulose, a vital excipient for pharmaceuticals, food, and cosmetics. It is renowned for product quality and innovation. The company serves a diverse global customer base.
Shelter Pharma Ltd:
On December 13, 2024, Shelter Pharma Ltd (BSE: SHELTER) opened at ₹54.00, recorded a high of ₹54.00 and a low of ₹52.52, closing at ₹53.45, down by 1.37%. The company’s market capitalisation stands at ₹61.79 crore.
Shelter Pharma Ltd reported revenue growth from ₹36.15 crore in FY23 to ₹40.02 crore in FY24, reflecting steady financial progress. The company achieved an impressive ROE of 24.98% and ROCE of 31.60%, supported by a low debt-to-equity ratio of 0.03, highlighting strong financial health and operational efficiency.
Shelter Pharma Ltd specialises in Ayurvedic and herbal healthcare products. It blends traditional formulations with modern manufacturing practices. The company has a strong domestic and international presence.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.